MAP2K7 and neuroblastoma: To determine if the combination of MEK inhibition and IGF1R inhibition would synergistically decrease viability in RAS-mutated neuroblastoma cells, we performed a matrix combination assay in which the viability of SK-N-AS cells was determined in the presence of 10 different concentrations of either trametinib or ganitumab (Figure 3A).